Claims for Patent: 10,195,197

Summary for Patent: 10,195,197

Title:	Combination therapy with glutaminase inhibitors
Abstract:	The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
Inventor(s):	Bennett; Mark K. (Moraga, CA), Gross; Matthew I. (Walnut Creek, CA), Bromley; Susan D. (San Francisco, CA), Orford; Keith (Doylestown, PA)
Assignee:	Calithera Biosciences, Inc. (South San Francisco, CA)
Application Number:	15/685,566
Patent Claims:	1. A method of treating cancer in a subject, comprising administering a glutaminase inhibitor and a taxane to the subject, wherein the subject is refractory to a taxane; the glutaminase inhibitor is ##STR00028## and the cancer is triple negative breast cancer. 2. The method of claim 1, wherein administering the taxane comprises administering paclitaxel, nab-paclitaxel, cabazitaxel or docetaxel. 3. The method of claim 1, wherein administering the taxane comprises administering paclitaxel. 4. The method of claim 1, wherein administering the taxane comprises administering docetaxel. 5. The method of claim 1, further comprising conjointly administering one or more additional chemotherapeutic agents. 6. The method of claim 5, wherein the one or more additional chemotherapeutic agents are selected from bortezomib, capecitabine, carboplatin, carfilzomib, cyclophosphamide, daunorubicin, doxorubicin, epirubicin, eribulin, fluorouracil, gemcitabine, ixabepilone, lenalidomide, methotrexate, mitoxantrone, mutamycin, rituximab, thiotepa, vincristine, and vinorelbine. 7. The method of claim 6, wherein the one or more additional chemotherapeutic agents are selected from bortezomib, carfilzomib, doxorubicin, lenalidomide, and rituximab. 8. The method of claim 5, wherein the additional chemotherapeutic agent is an immuno-oncology agent. 9. The method of claim 1, wherein the taxane to which the subject is refractory is paclitaxel or docetaxel. 10. The method of claim 9, wherein the taxane to which the subject is refractory is paclitaxel. 11. The method of claim 9, wherein the taxane to which the subject is refractory is docetaxel. 12. The method of claim 2, wherein the taxane to which the subject is refractory is paclitaxel or docetaxel. 13. The method of claim 12, wherein the taxane to which the subject is refractory is paclitaxel. 14. The method of claim 12, wherein the taxane to which the subject is refractory is docetaxel. 15. The method of claim 3, wherein the taxane to which the subject is refractory is paclitaxel or docetaxel. 16. The method of claim 15, wherein the taxane to which the subject is refractory is paclitaxel. 17. The method of claim 15, wherein the taxane to which the subject is refractory is docetaxel.

Details for Patent 10,195,197

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2039-02-26
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2039-02-26